We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Mumbai-based Navin Saxena Research & Technology (NSRT) plans to start Phase II clinical trial of Eflornithine granules 2.5 gm for the treatment of moderate COVID-19 infection by the first week of January 2021.
The trials will be conducted in four cities namely; Delhi, Lucknow, Pune, and Bengaluru and the company aims to complete the study in three to four months.